Alector

This page shows the latest Alector news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai pull plug on Alzheimer’s drug

One example is US biotech Alector, whose lead candidate AL002 targets a triggering receptor expressed on myeloid cells 2 (TREM2) and is based on a view that the disease is caused

Latest news

Alector kicks off next wave of biotech IPOs

Alector is pioneering immuno-neurology, a novel therapeutic that will treat a range of degenerative brain disorders by restoring healthy immune function to the brain. ... Hot on Alector’s heels is Stealth BioTherapeutics, which is aiming to raise $81
J&J and Bayer unveil new bioincubators

Places in J&J's bioincubators have already yielded funding and licensing deals for the likes of Alector, Bell Biosystems and Araxes Pharma.
J&J adds Manchester to partnering network

Alector is targeting key components of the pathological pathways that underlie Alzheimer's using monoclonal antibody technology via its strategic alliance with antibody discovery specialist Adimab. ... This agreement provides Alector with a lot of

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery

Angus Grant, CEO of the Dementia Discovery Fund, said: “I am delighted that Alector, the first of DDF’s investments, has reached this significant milestone. ... Alector’s progress serves as a great illustration of how the DDF’s investment choices